Lixisenatide

Chemical formula: C₂₁₅H₃₄₇N₆₁O₆₅S  Molecular mass: 4,858.56 g/mol  PubChem compound: 131704317

Active ingredient description

Lixisenatide is a selective GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of hypoglycaemia, the rescue mechanism of glucagon secretion is preserved.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
A10BJ03 A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues
Discover more medicines within A10BJ03

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
LYXUMIA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 320367-13-3
DrugBank Drug: DB09265
KEGG Drug: D09729
PubChem Compound: 131704317
RxNorm Ingredient: 1440051
SNOMED-CT Concept: 708808004
Lixisenatide (substance)
UNII Identifier: 74O62BB01U
LIXISENATIDE

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.